Given research setbacks and the known quantity that lambrolizumab is unlikely to receive approval prior to 2015, merger and acquisition activity will be critical to Merck’s pipeline expansion strategy and subsequent sales growth objectives in the next decade -
See more at: http://ycharts.com/analysis/story/merck_needs_acquisitions_heres_the_list
See more at: http://ycharts.com/analysis/story/merck_needs_acquisitions_heres_the_list